CN118339149A - 用于治疗与lpa受体活性相关的病症的化合物和组合物 - Google Patents

用于治疗与lpa受体活性相关的病症的化合物和组合物 Download PDF

Info

Publication number
CN118339149A
CN118339149A CN202280079337.9A CN202280079337A CN118339149A CN 118339149 A CN118339149 A CN 118339149A CN 202280079337 A CN202280079337 A CN 202280079337A CN 118339149 A CN118339149 A CN 118339149A
Authority
CN
China
Prior art keywords
compound
fibrosis
pharmaceutically acceptable
disease
solvate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280079337.9A
Other languages
English (en)
Chinese (zh)
Inventor
H·雷
Q·张
A·M·鲁文斯基
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rothschild Biotech
Original Assignee
Rothschild Biotech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/CN2021/125409 external-priority patent/WO2022083703A1/en
Application filed by Rothschild Biotech filed Critical Rothschild Biotech
Publication of CN118339149A publication Critical patent/CN118339149A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/428—Thiazoles condensed with carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/22—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D277/24—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/64—Benzothiazoles with only hydrocarbon or substituted hydrocarbon radicals attached in position 2

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202280079337.9A 2021-10-21 2022-10-21 用于治疗与lpa受体活性相关的病症的化合物和组合物 Pending CN118339149A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
CNPCT/CN2021/125409 2021-10-21
PCT/CN2021/125409 WO2022083703A1 (en) 2020-10-22 2021-10-21 Compounds and compositions for treating conditions associated with lpa receptor activity
CNPCT/CN2022/082072 2022-03-21
CN2022082072 2022-03-21
PCT/CN2022/126596 WO2023066359A1 (en) 2021-10-21 2022-10-21 Compounds and compositions for treating conditions associated with lpa receptor activity

Publications (1)

Publication Number Publication Date
CN118339149A true CN118339149A (zh) 2024-07-12

Family

ID=86057939

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280079337.9A Pending CN118339149A (zh) 2021-10-21 2022-10-21 用于治疗与lpa受体活性相关的病症的化合物和组合物

Country Status (5)

Country Link
US (1) US20240400562A1 (https=)
EP (1) EP4419509A4 (https=)
JP (1) JP2024540937A (https=)
CN (1) CN118339149A (https=)
WO (1) WO2023066359A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202342017A (zh) 2022-02-25 2023-11-01 美商洛子峰生物有限公司 用於治療與ｌｐａ受體活性相關的病狀的化合物及組合物

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060148830A1 (en) * 2002-10-03 2006-07-06 Ono Pharmaceutical Co., Ltd. Lpa receptor antagonist
WO2017223016A1 (en) * 2016-06-21 2017-12-28 Bristol-Myers Squibb Company Carbamoyloxymethyl triazole cyclohexyl acids as lpa antagonists
WO2020040326A1 (ko) * 2018-08-23 2020-02-27 가천대학교 산학협력단 페닐아세트산 유도체 및 이를 유효성분으로 함유하는 자가면역질환 예방 또는 치료용 조성물
WO2021097039A1 (en) * 2019-11-15 2021-05-20 Gilead Sciences, Inc. Triazole carbamate pyridyl sulfonamides as lpa receptor antagonists and uses thereof
CN116583501A (zh) * 2020-10-22 2023-08-11 罗特斯生物公司 用于治疗与lpa受体活性相关的病症的化合物和组合物

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060148830A1 (en) * 2002-10-03 2006-07-06 Ono Pharmaceutical Co., Ltd. Lpa receptor antagonist
WO2017223016A1 (en) * 2016-06-21 2017-12-28 Bristol-Myers Squibb Company Carbamoyloxymethyl triazole cyclohexyl acids as lpa antagonists
WO2020040326A1 (ko) * 2018-08-23 2020-02-27 가천대학교 산학협력단 페닐아세트산 유도체 및 이를 유효성분으로 함유하는 자가면역질환 예방 또는 치료용 조성물
WO2021097039A1 (en) * 2019-11-15 2021-05-20 Gilead Sciences, Inc. Triazole carbamate pyridyl sulfonamides as lpa receptor antagonists and uses thereof
CN116583501A (zh) * 2020-10-22 2023-08-11 罗特斯生物公司 用于治疗与lpa受体活性相关的病症的化合物和组合物

Also Published As

Publication number Publication date
JP2024540937A (ja) 2024-11-06
EP4419509A4 (en) 2025-10-15
US20240400562A1 (en) 2024-12-05
WO2023066359A1 (en) 2023-04-27
EP4419509A1 (en) 2024-08-28

Similar Documents

Publication Publication Date Title
AU2020341681B2 (en) RIP1 inhibitory compounds and methods for making and using the same
ES2943661T3 (es) Acidos carbamoil ciclohexílicos pirazol-O-ligados como antagonistas de LPA
AU2019262144B2 (en) RIP1 inhibitory compounds and methods for making and using the same
ES2962367T3 (es) Acidos carbamoil ciclohexílicos N-enlazados a pirazol como antagonistas de receptores del ácido lisofosfatídico (LPA)
ES2944304T3 (es) Pirazol azinas de ácido ciclohexílico como antagonistas de LPA
KR20200100719A (ko) Lpa 길항제로서의 시클로헥실 산 트리아졸 아진
JP2021507898A (ja) Ｌｐａアンタゴニストとしてのシクロヘキシル酸ピラゾールアゾール
JP7025555B2 (ja) 一過性受容体電位ａ１イオンチャネルの阻害
TW202245753A (zh) 用於治療疾病之類似物
US12428375B2 (en) Compounds and compositions for treating conditions associated with LPA receptor activity
CN120322431A (zh) 用于治疗与lpa受体活性相关的病症的化合物和组合物
EP4232431B1 (en) Compounds and compositions for treating conditions associated with lpa receptor activity
CN118339149A (zh) 用于治疗与lpa受体活性相关的病症的化合物和组合物
CN107089955B (zh) 磺酰胺类衍生物及其制备方法和用途
HK40112914A (zh) 用於治疗与lpa受体活性相关的病症的化合物和组合物
HK40127636A (zh) 用於治疗与lpa受体活性相关的病症的化合物和组合物
WO2025043079A1 (en) Compounds, compositions, and methods
HK40119559A (zh) 用於治疗与lpa受体活性相关的病症的化合物和组合物
HK40098770A (zh) 用於治疗与lpa受体活性相关的病症的化合物和组合物
HK40101053B (en) Compounds and compositions for treating conditions associated with lpa receptor activity
HK40101053A (en) Compounds and compositions for treating conditions associated with lpa receptor activity

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40112914

Country of ref document: HK